Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sentynl Therapeutics, Inc.

http://www.sentynl.com/

Latest From Sentynl Therapeutics, Inc.

Sentynl Signs Deal With Fortress’ Cyprium For ‘De-Risked’ Rare Disease Drug

Deal Snapshot: Sentynl will pay $20m in upfront and regulatory milestone payments through FDA approval, while Cyprium will retain 100% ownership of the priority review voucher.

Research & Development Deals

Subsys Makes A Bad Impression On FDA REMS Panel Members

CMS and FDA data showed prescriptions jumping while other fentanyl products were coming down.

Regulation Risk Management

Biomarker Diagnostics: Place Your Bets Wisely

Biomarker diagnostics are the linchpin of personalized medicine. But building a successful business around such tests is anything but straightforward, given the complexities associated with both their development and commercialization. Today's molecular diagnostic companies need to think carefully before they choose a "go it alone" strategy when developing a particular test. It may make more sense to forge a partnership with another diagnostic company or a drug developer with the goal of sharing costs and relative risks.

Medical Device Business Strategies

J&J's Franchise in Cancer Diagnostics

J&J isn't the ground-shaker in molecular testing that Roche Diagnostics is--so it is forging a different path to becoming a leader in emerging high-potential sectors of the in vitro diagnostics industry. It formed a subsidiary Veridex, dedicated to cancer diagnostics. That subsidiary is assembling a platform of core technologies and recently completed several deals, including in-licensing prostate cancer markers based on methylation, a hot area of research, from start-up Oncomethylome Sciences.

Innovation
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
UsernamePublicRestriction

Register